5-(4-三氟甲基苯基)-环己烷-1,3-二酮 | 55579-69-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-(4-三氟甲基苯基)-环己烷-1,3-二酮
• 英文名称: 5-<4-(trifluoromethyl)phenyl>-1,3-cyclohexanedione
• 英文别名: 5-cyclohexane-1,3-dione；5-(4-trifluoromethylphenyl)-1,3-cyclohexanedione；5-(4-trifluoromethylphenyl)cyclohexan-1,3-dione；5-(4-trifluoromethyl-phenyl)-cyclohexane-1,3-dione；5-(4-(Trifluoromethyl)phenyl)cyclohexane-1,3-dione；5-[4-(trifluoromethyl)phenyl]cyclohexane-1,3-dione
• CAS: 55579-69-6
• 化学式: C₁₃H₁₁F₃O₂
• mdl: MFCD00104794
• 分子量: 256.224
• InChiKey: HBUZHLJGLPSVNC-UHFFFAOYSA-N

物化性质

• 沸点：
  363.7±42.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  5-(4-三氟甲基苯基)-环己烷-1,3-二酮 在 盐酸 、 溶剂黄146 、 三氯化磷 作用下， 以 氯仿 为溶剂， 反应 5.0h， 生成 7-chloro-3,4-dihydro-3-<4-(trifluoromethyl)phenyl>-1,9(2H,10H)-acridinedione
  参考文献：
  名称：

  Antimalarial drugs. 64. Synthesis and antimalarial properties of 1-imino derivatives of 7-chloro-3-substituted-3,4-dihydro-1,9(2H,10H)-acridinediones and related structures

  摘要：

  To improve upon the activity and properties of the 3-aryl-7-chloro-3,4-dihydro-1,9(2H,10H)-acridinediones, a variety of 1-[(alkylamino)alkylene]imino derivatives (3) were prepared and shown to be highly active antimalarial agents in both rodents and primates. Among structural modifications prepared, including N-10-alkyl and C2-substituted analogs, removal of the C-9 oxygen, and introduction of an imino side chain at C-9, the imines of the N-10-H acridinediones were the most active compounds obtained. The [3-(NN-dimethylamino)propyl]imino derivative of 7-chloro-3-(2,4-dichlorophenyl)-3,4-dihydro-1,9(2H,10H)-acridinedione (9aa) proved to be highly active in advanced studies in primates.

  DOI：

  10.1021/jm00097a001
• 作为产物：
  描述：

  对三氟甲基苯甲醛 在 sodium hydroxide 、 硫酸 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 84.5h， 生成 5-(4-三氟甲基苯基)-环己烷-1,3-二酮
  参考文献：
  名称：

  Antimalarial drugs. 64. Synthesis and antimalarial properties of 1-imino derivatives of 7-chloro-3-substituted-3,4-dihydro-1,9(2H,10H)-acridinediones and related structures

  摘要：

  To improve upon the activity and properties of the 3-aryl-7-chloro-3,4-dihydro-1,9(2H,10H)-acridinediones, a variety of 1-[(alkylamino)alkylene]imino derivatives (3) were prepared and shown to be highly active antimalarial agents in both rodents and primates. Among structural modifications prepared, including N-10-alkyl and C2-substituted analogs, removal of the C-9 oxygen, and introduction of an imino side chain at C-9, the imines of the N-10-H acridinediones were the most active compounds obtained. The [3-(NN-dimethylamino)propyl]imino derivative of 7-chloro-3-(2,4-dichlorophenyl)-3,4-dihydro-1,9(2H,10H)-acridinedione (9aa) proved to be highly active in advanced studies in primates.

  DOI：

  10.1021/jm00097a001

文献信息

• [EN] SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY<br/>[FR] DIHYDROPYRIMIDINONES BICYCLIQUES SUBSTITUÉES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'ACTIVITÉ ÉLASTASE DE NEUTROPHILES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014135414A1

  公开（公告）日：2014-09-12

  This invention relates to substituted bicyclic dihydropyrimidinones of formula (1) and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及式（1）的取代双环二氢嘧啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
• Substituted tricyclics
  申请人：Eli Lilly and Company

  公开号：US06177440B1

  公开（公告）日：2001-01-23

  A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.

  一类新型三环化合物被披露，以及利用这类化合物抑制sPLA2介导的脂肪酸释放，用于治疗诸如感染性休克等疾病。
• Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity
  申请人：GNAMM Christian

  公开号：US20140249129A1

  公开（公告）日：2014-09-04

  This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及公式1的取代双环二氢嘧啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途，包含这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的方法。
• Trifluoroacetic Acid Catalyzed Cascade Reactions of 2,3‐Diketoesters with Cyclohexane‐1,3‐diones: Strategy Towards 4‐Hydroxybenzofuran Derivatives
  作者：Qiang Sha、Haixuan Liu、Yuan Li

  DOI：10.1002/adsc.201900056

  日期：2019.4

  An efficient trifluoroacetic acid catalyzed cascade reaction of 2,3‐diketoesters with cyclohexane‐1,3‐diones is described for the synthesis of a series of 4‐hydroxybenzofurans. This simple protocol has the advantages of easy operation, readily available starting materials, good functional group tolerance, and easily scale‐up. Subsequent derivatization of the 4‐hydroxybenzofurans provides a reasonable

  描述了一种有效的三氟乙酸催化的2,3-二酮酸酯与环己烷-1,3-二酮的级联反应，用于合成一系列的4-羟基苯并呋喃。这种简单的协议具有易于操作，易于获得的起始原料，良好的官能团耐受性和易于放大的优点。随后对4-羟基苯并呋喃进行衍生化提供了一条获得高度官能化苯并呋喃的合理途径。
• Substituted dihydropyridines and methods of use
  申请人：Hurt Ray Clarence

  公开号：US20070112015A1

  公开（公告）日：2007-05-17

  Compounds are provided that are modulators of the C5a receptor. The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.

  提供了调节C5a受体的化合物。这些化合物是取代二氢吡啶，并可用于制药组合物、治疗涉及C5a受体病理性激活的疾病和障碍的方法。